LBRX – lb pharmaceuticals inc (US:NASDAQ)
Stock Stats
News
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals (LBRX) had its price target raised by Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
LB Pharmaceuticals Inc GAAP EPS of -$0.45 [Seeking Alpha]
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
Form S-8 LB PHARMACEUTICALS INC
Form 10-K LB PHARMACEUTICALS INC For: Dec 31
Form 8-K LB PHARMACEUTICALS INC For: Mar 26
Form 8-K LB PHARMACEUTICALS INC For: Mar 13
Form 4 LB PHARMACEUTICALS INC For: Mar 06 Filed by: Lenz Robert A.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.